The coronavirus research renaissance

The post-SARS rush of research on human coronaviruses (CoVs) might not result in an immediate cure for SARS.

Written byKatherine Schlatter
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The post-SARS rush of research on human coronaviruses (CoVs) might not result in an immediate cure for SARS. But if recent publications are any indicator, it may fuel some solid insights into diseases such as the common pneumonias as well as the rare Kawasaki syndrome.

This year started with several papers that identified what may turn out to be at least two novel human coronaviruses that cause serious illness. First, a Hong Kong team that was one of the first to sequence the SARS CoV published findings of a new coronavirus, CoV-HKU1, which was present during the SARS outbreak.1 The discovery was a serendipitous one, according to the researchers who examined specimens obtained in early 2003 from patients suspected of having SARS.

K.Y. Yuen, who led the Hong Kong team, sees nothing extraordinary about the illness retrospectively diagnosed as CoV-HKU1. Unlike SARS, the virus' pathogenicity does not stand out. "We ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies